218 related articles for article (PubMed ID: 25339768)
1. Uneven genetic robustness of HIV-1 integrase.
Rihn SJ; Hughes J; Wilson SJ; Bieniasz PD
J Virol; 2015 Jan; 89(1):552-67. PubMed ID: 25339768
[TBL] [Abstract][Full Text] [Related]
2. Extreme genetic fragility of the HIV-1 capsid.
Rihn SJ; Wilson SJ; Loman NJ; Alim M; Bakker SE; Bhella D; Gifford RJ; Rixon FJ; Bieniasz PD
PLoS Pathog; 2013; 9(6):e1003461. PubMed ID: 23818857
[TBL] [Abstract][Full Text] [Related]
3. Identification of capsid mutations that alter the rate of HIV-1 uncoating in infected cells.
Hulme AE; Kelley Z; Okocha EA; Hope TJ
J Virol; 2015 Jan; 89(1):643-51. PubMed ID: 25339776
[TBL] [Abstract][Full Text] [Related]
4. Compensatory substitutions in the HIV-1 capsid reduce the fitness cost associated with resistance to a capsid-targeting small-molecule inhibitor.
Shi J; Zhou J; Halambage UD; Shah VB; Burse MJ; Wu H; Blair WS; Butler SL; Aiken C
J Virol; 2015 Jan; 89(1):208-19. PubMed ID: 25320302
[TBL] [Abstract][Full Text] [Related]
5. Contribution of the C-terminal region within the catalytic core domain of HIV-1 integrase to yeast lethality, chromatin binding and viral replication.
Xu Z; Zheng Y; Ao Z; Clement M; Mouland AJ; Kalpana GV; Belhumeur P; Cohen EA; Yao X
Retrovirology; 2008 Nov; 5():102. PubMed ID: 19014595
[TBL] [Abstract][Full Text] [Related]
6. Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.
Hassounah SA; Mesplède T; Quashie PK; Oliveira M; Sandstrom PA; Wainberg MA
J Virol; 2014 Sep; 88(17):9683-92. PubMed ID: 24920794
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.
Quashie PK; Oliviera M; Veres T; Osman N; Han YS; Hassounah S; Lie Y; Huang W; Mesplède T; Wainberg MA
J Virol; 2015 Mar; 89(6):3163-75. PubMed ID: 25552724
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and virological analysis of the 18-residue C-terminal tail of HIV-1 integrase.
Dar MJ; Monel B; Krishnan L; Shun MC; Di Nunzio F; Helland DE; Engelman A
Retrovirology; 2009 Oct; 6():94. PubMed ID: 19840380
[TBL] [Abstract][Full Text] [Related]
9. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
Nguyen HL; Ruxrungtham K; Delaugerre C
Intervirology; 2012; 55(4):287-95. PubMed ID: 22456540
[TBL] [Abstract][Full Text] [Related]
10. Correlation of recombinant integrase activity and functional preintegration complex formation during acute infection by replication-defective integrase mutant human immunodeficiency virus.
Li X; Koh Y; Engelman A
J Virol; 2012 Apr; 86(7):3861-79. PubMed ID: 22278243
[TBL] [Abstract][Full Text] [Related]
11. Second-site suppressors of HIV-1 capsid mutations: restoration of intracellular activities without correction of intrinsic capsid stability defects.
Yang R; Shi J; Byeon IJ; Ahn J; Sheehan JH; Meiler J; Gronenborn AM; Aiken C
Retrovirology; 2012 Apr; 9():30. PubMed ID: 22515365
[TBL] [Abstract][Full Text] [Related]
12. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
Hu Z; Kuritzkes DR
J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
[TBL] [Abstract][Full Text] [Related]
13. Role of human immunodeficiency virus type 1 integrase in uncoating of the viral core.
Briones MS; Dobard CW; Chow SA
J Virol; 2010 May; 84(10):5181-90. PubMed ID: 20219923
[TBL] [Abstract][Full Text] [Related]
14. Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity.
Anstett K; Cutillas V; Fusco R; Mesplède T; Wainberg MA
J Antimicrob Chemother; 2016 Aug; 71(8):2083-8. PubMed ID: 27084918
[TBL] [Abstract][Full Text] [Related]
15. INI1/hSNF5-interaction defective HIV-1 IN mutants exhibit impaired particle morphology, reverse transcription and integration in vivo.
Mathew S; Nguyen M; Wu X; Pal A; Shah VB; Prasad VR; Aiken C; Kalpana GV
Retrovirology; 2013 Jun; 10():66. PubMed ID: 23799881
[TBL] [Abstract][Full Text] [Related]
16. The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B.
Mesplède T; Quashie PK; Hassounah S; Osman N; Han Y; Liang J; Singhroy DN; Wainberg MA
AIDS; 2015 Jul; 29(12):1459-66. PubMed ID: 26244385
[TBL] [Abstract][Full Text] [Related]
17. In vitro functional analyses of the human immunodeficiency virus type 1 (HIV-1) integrase mutants give new insights into the intasome assembly.
Cellier C; Moreau K; Gallay K; Ballandras A; Gouet P; Ronfort C
Virology; 2013 May; 439(2):97-104. PubMed ID: 23473371
[TBL] [Abstract][Full Text] [Related]
18. Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses.
Pham HT; Mesplède T; Wainberg MA
Retrovirology; 2016 Apr; 13(1):31. PubMed ID: 27130466
[TBL] [Abstract][Full Text] [Related]
19. The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration.
Mesplède T; Leng J; Pham HT; Liang J; Quan Y; Han Y; Wainberg MA
mBio; 2017 Apr; 8(2):. PubMed ID: 28377526
[TBL] [Abstract][Full Text] [Related]
20. Reversion of the lethal phenotype of an HIV-1 integrase mutant virus by overexpression of the same integrase mutant protein.
Priet S; Navarro JM; Quérat G; Sire J
J Biol Chem; 2003 Jun; 278(23):20724-30. PubMed ID: 12670953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
